Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital-Reference-Cited by-同舟云学术

Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital

Published:2023-10 Issue:10 Volume:7 Page:e964
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Danesin Nicolò¹,Lo Schirico Mariella¹,Scapinello Greta¹,Grassi Angela²,Riva Marcello³,Berno Tamara¹,Branca Antonio¹,Visentin Andrea¹,Carraro Marco¹,Pavan Laura¹,Manni Sabrina¹⁴,Bonaldi Laura²,Martines Annalisa²,Bertorelle Roberta²,Vianello Fabrizio¹⁴,Gurrieri Carmela¹,Briani Chiara⁵,Zambello Renato¹⁴,Trentin Livio¹,Piazza Francesco¹⁴^ORCID

Affiliation:

1. Hematology Unit, Department of Medicine, University of Padova, Italy

2. Immunology and Molecular Oncology Diagnostic Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy

3. San Bortolo Hospital, Hematology and Cell Therapy Division, Vicenza, Italy

4. Veneto Institute of Molecular Medicine, Fondazione per la Ricerca Biomedica Avanzata, Padova, Italy

5. Department of Neurosciences, University of Padova, Italy

Publisher

Wiley

Subject

Hematology

Reference16 articles.

1. Two interesting syndromes with hyperglobulemia (purpura hyperglobulinemia and macroglobulinemia).;Waldenstrom;Schweiz Med Wochenschr,1948

2. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms.;Alaggio;Leukemia,2022

3. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.;D’Sa;Br J Haematol,2017

4. International prognostic scoring system for Waldenstrom macroglobulinemia.;Morel;Blood,2009

5. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenstrom’s macroglobulinemia: final analysis from the randomized phase III iNNOVATE study.;Buske;J Clin Oncol,2022